Author pages are created from data sourced from our academic publisher partnerships and public sources.
Share This Author
Intratumor heterogeneity and branched evolution revealed by multiregion sequencing.
Intratumor heterogeneity can lead to underestimation of the tumor genomics landscape portrayed from single tumor-biopsy samples and may present major challenges to personalized-medicine and biomarker development.
Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade
A relationship between clonal neoantigen burden and overall survival in primary lung adenocarcinomas and the impact of neoantigens intratumor heterogeneity (ITH) on antitumor immunity is demonstrated.
Genomic architecture and evolution of clear cell renal cell carcinomas defined by multiregion sequencing
It was found that 73–75% of identified ccRCC driver aberrations were subclonal, confounding estimates of driver mutation prevalence, and the proportion of C>T transitions at CpG sites increased during tumor progression.
Tracking the Evolution of Non‐Small‐Cell Lung Cancer
- M. Jamal-Hanjani, G. Wilson, C. Swanton
- Medicine, BiologyThe New England journal of medicine
- 26 April 2017
Intratumor heterogeneity mediated through chromosome instability was associated with an increased risk of recurrence or death, a finding that supports the potential value of chromosome instability as a prognostic predictor.
Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition)
There continues to be confusion regarding acceptable methods to measure autophagy, especially in multicellular eukaryotes, so it is important to update guidelines for monitoring autophagic activity in different organisms.
Preexisting and de novo humoral immunity to SARS-CoV-2 in humans
Using diverse assays for antibodies recognizing SARS-CoV-2 proteins, preexisting humoral immunity was detected and antibodies targeting the S2 subunit were particularly prevalent in children and adolescents.
Genomic Features of Response to Combination Immunotherapy in Patients with Advanced Non-Small-Cell Lung Cancer
Development of tumor mutation burden as an immunotherapy biomarker: utility for the oncology clinic
- T. Chan, M. Yarchoan, S. Peters
- Biology, MedicineAnnals of oncology : official journal of the…
- 5 November 2018
TMB, in concert with PD-L1 expression, has been demonstrated to be a useful biomarker for ICB selection across some cancer types; however, further prospective validation studies are required.
Phylogenetic ctDNA analysis depicts early stage lung cancer evolution
It is shown that phylogenetic ct DNA profiling tracks the subclonal nature of lung cancer relapse and metastasis, providing a new approach for ctDNA-driven therapeutic studies.
deconstructSigs: delineating mutational processes in single tumors distinguishes DNA repair deficiencies and patterns of carcinoma evolution
- R. Rosenthal, N. McGranahan, J. Herrero, B. Taylor, C. Swanton
- Medicine, BiologyGenome Biology
- 22 February 2016
DeconstructSigs confers the ability to define mutational processes driven by environmental exposures, DNA repair abnormalities, and mutagenic processes in individual tumors with implications for precision cancer medicine.